血液透析相关血糖紊乱:持续葡萄糖监测揭示的无症状低血糖
本研究用持续葡萄糖监测评估98例接受血液透析的2型糖尿病患者(透析液葡萄糖浓度100、125或150 mg/dL)的血糖波动。结果显示,无论透析液葡萄糖浓度如何,传感器葡萄糖水平在透析期间持续下降,49例(50%)达到低于透析液葡萄糖浓度的最低点,21例(21%)出现透析相关低血糖且均无症状。血糖波动指标较高者更易发生透析相关低血糖。
要点
- 使用含100-150 mg/dL葡萄糖的透析液仍频繁发生无症状性透析相关低血糖。
- 透析期间传感器葡萄糖可持续下降至低于透析液葡萄糖浓度。
- 血糖波动较大的患者透析相关低血糖风险更高。
核心结论
- 尽管使用含100-150 mg/dL葡萄糖的透析液,接受血液透析的糖尿病患者仍频繁发生无症状性透析相关低血糖。
- 传感器葡萄糖在透析接近结束时可能降至远低于透析液葡萄糖浓度。
研究设计与样本
- 研究纳入98例接受血液透析的2型糖尿病患者,其中68例为男性,使用持续葡萄糖监测评估血糖谱。
- 透析液葡萄糖浓度为100、125或150 mg/dL。
- HbA1c为6.4 ± 1.2%,糖化白蛋白为20.8 ± 6.8%。
主要发现
- 传感器葡萄糖水平在透析期间持续下降,与透析液葡萄糖浓度无关。
- 49例(50%)参与者达到低于透析液葡萄糖浓度的最低点。
- 21例(21%)出现透析相关低血糖(定义为透析期间和/或透析结束至下一餐前传感器葡萄糖<70 mg/dL),且所有发作均无症状。
- 发生透析相关低血糖者的血糖波动指标(标准差、变异系数、传感器葡萄糖范围)更高,低于范围时间(<70 mg/dL)更低。
- 两组间70-180 mg/dL范围内时间、高于范围时间(>180 mg/dL)、HbA1c和糖化白蛋白相似。
关键数值与推荐
- 透析相关低血糖定义为透析期间和/或透析结束至下一餐前传感器葡萄糖<70 mg/dL。
- 透析液葡萄糖浓度为100、125或150 mg/dL。
临床怎么用
- 对接受血液透析的糖尿病患者应警惕无症状性透析相关低血糖,即使使用含葡萄糖透析液。
- 持续葡萄糖监测有助于识别透析期间及透析后至下一餐前的低血糖风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is a high risk of asymptomatic hypoglycemia associated with hemodialysis (HD) using glucose-free dialysate; therefore, the inclusion of glucose in the dialysate is believed to prevent intradialytic hypoglycemia. However, the exact glycemic fluctuation profiles and frequency of asymptomatic hypoglycemia using dialysates containing >100 mg/dL glucose have not been determined. RESEARCH DESIGN AND METHODS: We evaluated the glycemic profiles of 98 patients, 68 of whom were men, with type 2 diabetes undergoing HD (HbA1c 6.4 ± 1.2%; glycated albumin 20.8 ± 6.8%) with a dialysate containing 100, 125, or 150 mg/dL glucose using continuous glucose monitoring. RESULTS: Sensor glucose level (SGL) showed a sustained decrease during HD, irrespective of the dialysate glucose concentration, and reached a nadir that was lower than the dialysate glucose concentration in 49 participants (50%). Twenty-one participants (21%) presented with HD-related hypoglycemia, defined by an SGL <70 mg/dL during HD and/or between the end of HD and their next meal. All these hypoglycemic episodes were asymptomatic. Measures of glycemic variability calculated using the SGL data (SD, coefficient of variation, and range of SGL) were higher and time below range (<70 mg/dL) was lower in participants who experienced HD-related hypoglycemia than in those who did not, whereas time in range between 70 and 180 mg/dL, time above range (>180 mg/dL), HbA1c, and glycated albumin of the two groups were similar. CONCLUSIONS: Despite the use of dialysate containing 100-150 mg/dL glucose, patients with diabetes undergoing HD experienced HD-related hypoglycemia unawareness frequently. SGL may fall well below the dialysate glucose concentration toward the end of HD.
引用
- Hayashi A, Shimizu N, Suzuki A, et al. Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia. Diabetes Care. 2021. PMID: 34045240. doi:10.2337/dc21-0269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。